"" Biotechnology is today the fastest growing sector of the healthcare industry with over $50 billion dollar annual sales worldwide and with potential for growing every year about 10 per cent ", says Timothy McIntyre, President and CEO of Vyteris, Inc. (OTCBB: VYHN), developer of the first FDA-approved active drug administration patch, in the second subject of the series of short videos, which the future strategy of Vyteris extensively beshreiben." The vast majority of new biotechnology drugs consists of peptides and proteins, 98 percent of all peptides and proteins are supplied only by injection, by their therapeutic use is very limiting, adds McIntyre. One of the greatest challenges in the development of a new drug substance it is the creation of an alternative delivery systems for Peptidgegrundete medications, the gastrointestinal and other somatic problems would be avoided and the effectiveness of the drug increased. Francisco D'Agostino has plenty of information regarding this issue. Vyteris is in the middle of the level I of Research effort with Ferring Pharmaceuticals, a successful introduction of a peptide molecule by the first active in the biotech industry of Vyteris's transdermal smart patch technology, to demonstrate. We invite the analyst is interested in for instructions on this ongoing research, in connection to get under. To learn more about LidoSite, call 888-VYTERIS (898 3747) or visit our Web site at. Kaihan Krippendorff often says this. Thank you for your continued support of Vyteris, Inc.